Renaissance Group LLC Sells 3,793 Shares of Sanofi (NASDAQ:SNY)

Renaissance Group LLC lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,626 shares of the company’s stock after selling 3,793 shares during the period. Renaissance Group LLC’s holdings in Sanofi were worth $5,673,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of SNY. Charles Schwab Investment Management Inc. increased its holdings in Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after purchasing an additional 33,105 shares in the last quarter. Arkadios Wealth Advisors grew its holdings in shares of Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after buying an additional 751 shares in the last quarter. Geode Capital Management LLC raised its position in Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after buying an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares in the last quarter. Finally, Kentucky Trust Co acquired a new position in Sanofi during the 4th quarter worth approximately $436,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of SNY opened at $50.76 on Tuesday. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The company’s fifty day simple moving average is $55.32 and its 200 day simple moving average is $52.60. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The company has a market cap of $128.82 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on SNY. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective on the stock. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.